Center for Drug Evaluation and Research (CDER) Director Janet Woodcock gave a less than enthusiastic reception to an idea of applying breakthrough therapy designation principles to potential generic competitors.
Testifying before the House Energy and Commerce Subcommittee on Health at a March 22 hearing on user fees, Woodcock cautioned...
